Table 2 Univariate and multivariate analysis of clinical variables and ATP1As for OS
Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
FIGO stage (stage I–II vs. stage III–IV) | 2.085 (0.925–4.699) | 0.076 | 1.638 (0.392–6.854) | 0.499 |
Histologic grade (G1–2 vs. G3–4) | 1.194 (0.797–1.789) | 0.389 | ||
Primary therapy outcome (PR-CR vs. SD-PD) | 0.306 (0.207–0.451) | < 0.001 | 0.247 (0.161–0.38) | < 0.001 |
Age (< 60 vs. ≥ 60) | 1.329 (1.025–1.722) | 0.032 | 1.305 (0.948–1.794) | 0.102 |
Tumor residual (NRD vs. RD) | 2.302 (1.479–3.583) | < 0.001 | 2.149 (1.285–3.594) | 0.004 |
Lymphatic invasion (no vs. yes) | 1.422 (0.839–2.411) | 0.191 | ||
Venous invasion (no vs. yes) | 0.905 (0.487–1.683) | 0.753 | ||
Anatomic subdivision (unilateral vs. bilateral) | 1.041 (0.768–1.41) | 0.798 | ||
TP53 mutation (no vs. yes) | 0.692 (0.423–1.132) | 0.143 | ||
BRCA mutation (no vs. yes) | 0.65 (0.361–1.171) | 0.152 | ||
ATP1A1 (low vs. high) | 1.148 (0.885–1.49) | 0.298 | ||
ATP1A2 (low vs. high) | 1.257 (0.968–1.632) | 0.086 | 1.564 (1.134–2.157) | 0.006 |
ATP1A3 (low vs. high) | 1.6 (1.232–2.077) | < 0.001 | 1.932 (1.397–2.673) | < 0.001 |
ATP1A4 (low vs. high) | 0.748 (0.575–0.972) | 0.03 | 0.555 (0.4–0.771) | < 0.001 |